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SUMMARY 
Dendritic cells (DCs) play a key role in orchestrating adaptive immune responses. In 
human blood, three distinct subsets exist: plasmacytoid DCs (pDCs) and BDCA3+ 
and CD1c+ myeloid DCs. In addition, a DClike CD16+ monocyte has been reported. 
Although RNA-expression profiles have been previously compared, protein 
expression data may provide a different picture. Here, we exploited label-free 
quantitative mass spectrometry to compare and identify differences in primary 
human DC subset proteins. Moreover, we integrated these proteomic data with 
existing mRNA data to derive robust cell-specific expression signatures with more 
than 400 differentially expressed proteins between subsets, forming a solid basis for 
investigation of subset-specific functions. We illustrated this by extracting subset 
identification markers and by demonstrating that pDCs lack caspase-1 and only 
express low levels of other inflammasome related proteins. In accordance, pDCs 
were incapable of interleukin (IL)-1b secretion in response to ATP.  
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INTRODUCTION 
Dendritic cells (DCs) play a critical role in the initiation of antigen specific adaptive 
immune responses to foreign antigens and the maintenance of tolerance to self-
antigens (reviewed by Balan et al., 2014; Reynolds and Haniffa, 2015; Vu Manh et 
al., 2015). DCs harbor the unique capacity to process and present antigens 
complexed to either major histocompatibility complex (MHC) class I or MHC class II 
and thereby can activate naive T cells. It is because of this ability that DCs have 
become of interest as tools or targets for cancer immunotherapy to initiate or boost 
tumor immunity.  
Several DC subsets can be distinguished that differ in their ability to sense and 
respond to pathogens and in the type of immune response they initiate. Two main 
types of naturally occurring blood DCs have been characterized: plasmacytoid DCs 
(pDCs) and myeloid DCs (mDCs) (reviewed by Vu Manh et al.,2015). pDCs play a 
key role in antiviral immunity, through their ability to produce large amounts of type I 
interferons (IFNs). mDCs represent the ‘‘traditional’’ antigen-presenting DCs that can 
be further subdivided based on the expression of BDCA3 (CD141) and CD1c 
(BDCA1). Each can be defined through the expression of different pattern 
recognition receptors (PRRs; e.g., Toll-like receptors [TLRs] and C-type lectin 
receptors [CLRs]) and the secretion of a distinct set of cytokines upon stimulation 
(reviewed by Balan et al., 2014; Reynolds and Haniffa, 2015; Vu Manh et al., 2015). 
Whereas CD1c+ mDCs express most TLRs, except TLR9, BDCA3+ mDCs express 
mainly TLR3. Furthermore, BDCA3+ mDCs express the CLR CLEC9a, which 
facilitates the uptake of dying cells and subsequent cross-presentation of derived 
antigens to T cells (Ahrens et al., 2012; Jongbloed et al., 2010; Poulin et al., 2010). 
Finally, although not considered a genuine DC, a CD16+ subset of monocytes, 
coined ‘‘non-classical monocytes,’’ can be found in blood with DC-like properties 
(Ziegler-Heitbrock et al., 2010). So far, these DCs subsets have been mostly 
characterized and isolated based on cell-specific (surface) markers and functionally 
compared for abilities such as antigen presentation, cytokine secretion, and 
migration (Balan et al., 2014; Reynolds and Haniffa, 2015; Vu Manh et al., 2015). 
These functional assays, however, can be biased as they provide information on 
only a few a priori determined functional responses to a limited set of activation 
stimuli and antigens. Although highly valuable in investigating the abilities of each 
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subset under specific circumstances, these assays may leave more untraditional 
unique characteristics of each subset undetected. To overcome this, unbiased 
analyses of mRNA expression of human and mouse DC subsets have been 
performed and proven to be highly informative (Lindstedt et al., 2005; Manh et al., 
2013; Miller et al., 2012; Robbins et al., 2008). Comparative transcriptome analysis 
delivered the most compelling evidence for the current thought that the human 
BDCA3+ mDC is the counterpart of the murine CD8a+ DC, despite the lack of 
conservation of identification markers (Robbins et al., 2008). In addition, the Robbins 
et al. (2008) study demonstrated that the CD16+ DC-like cell, based on its full 
transcriptional program, resembles a monocyte more than a DC. Although these 
studies have provided valuable insight into the relation between DC subsets in mice 
and humans, RNA expression does not always reflect protein expression. Since not 
all RNA is translated, RNA and proteins may have dissimilar half-lives and kinetics, 
and protein levels may also be regulated by post-transcriptional modifications. 
Furthermore transcriptomics does not take into account pre-existing protein levels, 
alterations in translation efficiency, or protein stability. Therefore, transcriptome 
expression data may have limited predictive power on which proteins really define 
each DC subset and may have left important phenotypic and functional differences 
unnoticed. To confirm and supplement the existing transcriptome analysis, we have 
performed a comprehensive mass-spectrometry (MS)-based quantitative proteome 
comparison of rare blood DC subsets. Furthermore, we integrated protein and RNA 
data to derive expression signatures that give a more reliable and comprehensive 
account of expression differences than can be achieved from using either technique 
alone. The expression signatures represent an easily accessible resource to derive 
hypotheses on subset-specific functions. To illustrate this, we validated five of the 
identified differentially expressed surface markers and showed that caspase-1 is 
completely lacking in pDCs, which is accompanied by restricted expression of other 
inflammasome components and affects the function of these cells. 
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RESULTS 
Quantitative Proteomics of Primary Human DC Subsets 
For proteome characterization, four DC-(like) subsets (i.e., pDCs, CD1c+ mDCs, 
BDCA3+ mDCs, and CD16+ monocytes) were isolated from apheresis products 
obtained from healthy volunteers by magnetic-bead-based cell separation. The purity 
of the isolated cells and presence of cross-contamination were assessed by flow 
cytometry (Figure S1). For pDCs, CD1c+ mDCs, and CD16+ monocytes, high purity 
(R95%) was obtained for all subsets without major cross-contamination or presence 
of B or T cells in two out of three donors. For a third donor, medium-high purity was 
obtained (78%–92%). For BDCA3+ mDC samples, most cells were BDCA3+CD11c+ 
(87%–95%). We observed however, a variable number of CD11c+ cells expressing 
intermediate levels of BDCA3 (BDCA3int) in the isolate together with cells positive 
for CD1c+, indicating cross-contamination of this sample with 
CD11c+CD1c+BDCA3int cells. Therefore, we consider these samples to be BDCA3+ 
mDC enriched rather than pure. Nevertheless, we reasoned that this sample is still of 
use to derive BDCA3+ mDC-specific protein expression, which may be achieved by 
relating the BDCA3+ mDC-enriched samples to the (BDCA3+-depleted) CD1c+ mDC 
samples. All 12 (three donors times four subsets) samples were, first, each 
separated using SDS-PAGE, fractionated into 20 fractions, and subjected to in-gel 
trypsin digestion (yielding 240 fractions in total). The fractions were measured in 
triplicate, using highly sensitive liquid chromatography-tandem MS (LC-MS/MS) for 
maximal protein coverage. After peptide identification and sequence alignment, 
proteins were quantified using the label free quantification (LFQ) algorithm in 
MaxQuant (Cox et al.,2014). The Pearson correlation was very high (r = 0.97 ± 0.02) 
between technical replicates and high (r = 0.93 ± 0.02) between biological replicates 
(e.g., the same subsets from different donors), indicating good reproducibility across 
measurements and donors (Table S1). In total, we identified 42,723 non-redundant 
peptide sequences corresponding to 4,196 protein groups (Table S2; Table S3). 
Requiring a protein to be expressed in at least two donors for each subset, we 
identified 2,351, 2,197, 2,009, and 1,883 proteins in pDCs, BDCA3+ mDCs, CD1c+ 
mDCs, and CD16+ cells, respectively, and 2,823 proteins overall (Figures S2A–S2D; 
Tables S2 and S3). Next, using the CORUM database of protein complexes, we 
inspected the identification of components of protein complexes essential for cell 
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homeostasis (e.g., mitochondrial complexes and proteasomes), to assess the 
completeness of the proteome in each cell type (Luber et al., 2010). We recovered 
most components, indicating that our proteome covered the majority of DC proteins 
(Figure S2E). Coverage was best in pDCs and BDCA3+ mDCs, yielding 70%–100% 
of essential protein complexes, and was least in CD16+ cells (40%–100%; Figure 
S2E).  
We then evaluated the assignment of key identification markers for each subset. No 
markers specific for other major leukocyte populations (e.g., T, B, or NK cells) were 
identified, suggesting a lack of substantial contamination with other leukocytes. In 
contrast, we readily identified the unique expression of at least one previously 
reported subset-specific protein for each subset, including TLR7, TLR9, CLEC4C, 
NRP1, and IL3RA for pDCs; IDO and HLA-DO for BDCA3+ mDCs; and CD16 
(FCGR3A) for CD16+ monocytes (Table 1). Importantly, CD1c was uniquely 
detected in CD1c+ mDCs but not in BDCA3+ mDCs. For BDCA3+ DCs, we did not 
immediately identify more traditional markers such as BDCA3 (CD141, THBD), 
CLEC9a, TLR3, NECL2, and XCR1 using the default peptide identification threshold 
(false discovery rate [FDR] = 0.01). Possibly, this was due to a low expression, high 
hydrophobicity, or heavy glycosylation of these molecules. Nevertheless, we found a 
unique expression of IDO and HLA-DO in BDCA3+ mDCs; they were previously 
reported to be highly expressed in especially this subset (Crozat et al., 2010; Hornell 
et al., 2006). Upon more close inspection of peptides, however, TLR3 was found in 
one BDCA3+ mDC sample, and CLEC9A and BDCA3 (CD141 / THBD) were found 
in two samples. Because these peptides were detected with low confidence (FDR = 
1), we generated MS/MS spectra and manually verified this result (data not shown). 
Together, the expression patterns of established marker proteins demonstrate the 
ability of our approach to discern the distinct identity of each subset.  
We also obtained quantitative information using the LFQ algorithm in MaxQuant 
(Cox et al., 2014). First, we used this information to compare protein expression in 
the three main populations of blood DC-like cells (i.e., pDCs, CD1c+ mDCs, and 
CD16+ monocytes), excluding the BDCA3+ mDC samples. We calculated average 
expression differences between any two subsets and visualized these in volcano 
plots (Figure 1A; see Table S4 for complete statistical analysis). It should be noted 
that here and in the remainder of the manuscript, only proteins expressed in at least 
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two donors in one of the cell types being compared are included. Pairwise 
comparisons further highlighted subset identity, showing specific expression of 
CD11c (ITGAX/ITGB2) in myeloid cells and overexpression in the pDCs of several 
proteins with a reported pDC-specific expression and function (e.g., PACSIN1, 
SLC14A4, IRF7, TCF4, BCL11A, BLNK, and CD2AP) (Blasius et al., 2010; Cisse et 
al., 2008; Crozat et al., 2010; Esashi et al., 2012; Marafioti et al., 2008; Robbins et 
al., 2008; Rock et al., 2007; Wu et al., 2013).  
Next, we determined the relation between cell types by hierarchical clustering 
(Figure 1B). Based on all proteins, subsets clustered together mostly on cell type 
rather than on donor. Furthermore, CD16+ monocytes and CD1c+ mDCs that share 
a myeloid origin were closer to each other than to pDCs. Hierarchical clustering of 
samples based on 1,218 differentially expressed proteins (DEPs) between the three 
subsets showed a separation similar to that seen when using all proteins and 
indicated six main groups of DEPs that showed higher or lower expression in one of 
the three subsets (Figure 1C). Next, we assessed how our protein data related to 
mRNA data. We merged our protein data with a previously published and publicly 
available microarray dataset of the same subsets (Lindstedt et al., 2005). For one of 
the donors that was used for MS analysis, we also acquired sufficient material to 
perform RNA sequencing on the same sample (Table S5). We first assessed the 
overall correlation between microarray-derived RNA data and proteome data for 
each cell type and found this to be low, similar to our previous observations (Figure 
1D; r = 0.28–0.31) (Buschow et al., 2010). The correlation between RNA-sequencing 
data and proteome data for the matched donor was slightly better (0.37–0.45). 
Cross-correlation of this RNA-sequencing dataset to the protein data of the two other 
donors, however, produced a similar correlation, indicating that the different RNA 
analysis method was mostly responsible for the improved correlation (Table S6). To 
make a more in-depth comparison of the RNA data to our proteome dataset possible, 
we transformed both microarray-derived RNA and protein expression data to relative 
expression levels for each dataset separately (Z scores, mean to 0, variance to 1). 
From the merged dataset, we yielded 742 DEPs for which also RNA data were 
available. Again, we used the merged RNA and protein data for these 742 DEPs as 
input for hierarchical clustering (Figure 1E; Table S6). The combined protein and 
RNA samples grouped the distinct subsets from the two datasets together, indicating 
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that, despite moderate correlation between absolute expression levels, there was a 
good correlation between RNA and protein expression patterns (Figure 1E). 
Importantly, the clustering was determined neither by biological variation between 
donors nor by technical variation between omics technologies. 
 
Generation of Protein-Based Expression Signatures and Networks 
Protein and RNA data were not consistent in all cases, and proteome analysis put 
forward DEPs for which differences at the RNA level were only minor or for which no 
probes had been present on the microarray chips. Next, we set out to visualize were 
exactly proteome analysis pointed to not previously appreciated differences between 
DC subsets and the cases in which RNA and protein were in agreement. For the six 
groups of DEPs associated with the three subsets (Figure 1C), we generated protein 
expression signatures based on four different evidence levels: (I) subset-specific 
protein expression/absence, supported by RNA data; (II) differential protein 
expression between subsets, supported by RNA data; (III) subset-specific protein 
expression/ absence, not supported by RNA data; and (IV) differential protein 
expression between subset, not supported by RNA data (Figure 2; Supplemental 
Experimental Procedures). Proteins included in signatures based on level I and level 
II evidence behaved consistently in RNA and protein datasets. These proteins are, 
thus, likely mostly regulated at the transcriptional level. Importantly, for these 
proteins, proteomics data confirmed RNA-identified differences between subsets. 
Many established markers were present in these two groups: e.g., IL3RA, CLEC4C, 
TLR9, CD1c, and FCGR3B (CD16). Supported by two lines of evidence, other 
proteins in these groups now represent high-potential subset identification markers 
and include CD163 for CD1c+ mDCs and SIGLEC10 for CD16+ monocytes (Figure 
2; Table S7). In contrast, proteins included in signatures based on level III and level 
IV evidence reflect less consistency between protein and RNA expression patterns 
or a lack of transcriptional information/ChIP (chromatin immunoprecipitation) 
annotation. Proteins in these evidence groups represent the added value of the 
proteome analysis (Figure 2). Finally, proteins that were put forward as differentially 
expressed by RNA data (differentially expressed genes; DEGs), and that were also 
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present in our protein dataset but were not confirmed as differentially expressed by 
proteomics, are listed in Table S8.  
Together, we confirmed differential or unique expression of 253 proteins between the 
three subsets previously observed by RNA expression (pDCs, 109 higher/65 lower; 
CD1c+ mDCs, 17 higher/1 lower; CD16+ monocytes, 34 higher/27 lower) that could 
also be derived from the transcriptome data (levels I and II; Figure 3; Table S7, 
including lower confidence DEPs). In addition, 143 proteins were found to be 
differently/uniquely expressed between subsets based on proteomics data only 
(levels III and IV), which hold yet-unappreciated differences between DC subsets 
(pDCs, 75 higher/14 lower; CD1c+ mDCs, 10 higher/8 lower; CD16+ monocytes, 10 
higher/26 lower). To obtain insight into the overall function of signature proteins, we 
performed a protein-protein interaction (PPI) analysis and a functional annotation 
(FA) analysis (Figure 3; Table S9). PPI analysis demonstrated good connectivity 
between proteins high in pDCs (0.73 connection per protein), proteins low in pDCs (1 
connection per protein), those high in CD1c+ mDCs (0.85 connection per protein), 
and those low in CD16+ monocytes (0.64 connection per protein) (Figure 3; Table 
S9). Much less connectivity was found between proteins high in CD16+ monocytes 
(0.25 connection per protein) and those low in CD1c+ mDCs (no connections were 
identified).  
In the CD1c+ mDC high signature, the MCM family and accessory proteins that 
regulate the cell cycle were found by proteome analysis only and were highly 
connected, suggesting a unique role for this complex in CD1c+ mDCs (Figure 3; 
Table S9). This complex was completely absent from CD16+ monocytes. Proteome 
analysis, but not RNA analysis, also pointed out that CD1c+ mDCs more highly 
expressed both the alpha-chain and the beta-chain of HLA-DQ, which may, thus, be 
of specific importance in this DC subset. The largest gene signatures were obtained 
for pDCs and mostly mapped to expected pDC functions, including TLR and IFN 
signaling (e.g., TLR9, IRF7, IRF8, and SMAD3), but also to endoplasmic reticulum 
(ER), Golgi, and vesicular transport, indicating high protein biosynthesis in this cell 
type (e.g., SEC24A, SEC31A, SEC11C, PDIA5, PDIA4, ERGIC3, and LMAN1) 
(Figure 3; Table S9). Intriguingly, IFN and TLR signalling pathway constituents were 
highly expressed in pDCs by both RNA and protein analyses, while proteins involved 
in protein biosynthesis and vesicular transport were, in many cases, highly 
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expressed at the protein level only (Figure 3). The proteins absent from pDCs (e.g., 
shared by CD1c+ mDCs and CD16+ monocytes) were also highly connected and 
related to cell adhesion and protrusion formation (e.g., ZYX, MSN, PAK1, VASP, and 
FSCN1; Table S9), in line with the rounder non-adhesive phenotype of pDCs. 
Furthermore, pDCs hardly expressed or even lacked TLR2, which detects bacterial 
lipoproteins, several proteins connected to bactericidal endo/phagosomes 
(e.g.,HMOX1, NCF2, and RAB27a) and CASP1 (caspase-1), a crucial enzyme in the 
inflammasome-induced cleavage of interleukin (IL)-1b in macrophages and DCs 
(Figure 3; Table S9). 
BDCA3+ versus CD1c+ mDCs 
Next, we investigated the difference between the two myeloid DC subsets. Despite 
the presence of CD1c+ mDCs in the BDCA3+ mDC samples, mDC samples were 
largely devoid of other blood cells (Figure S1). Importantly, CD1c+ mDC samples 
were devoid of BDCA3+ mDCs. A direct comparison between the two sets of 
samples could, therefore, still reveal important expression differences between mDC 
subsets (Figure 4; Table S4). As expected, the number of DEPs between BDCA3+ 
mDCs and CD1c+ mDCs was much less than between other subsets, reflecting the 
presence of CD1c+ cells in both samples and/or their more common origin. Similar to 
what we found before, protein only moderately correlated to RNA expression (r = 
0.31 for microarray or r = 0.38 for RNA sequencing; Figure 4B; Table S6). Despite 
the contamination with CD1c+ mDCs, the BDCA3+ mDC protein samples clustered 
with the microarray RNA samples of BDCA3+ mDCs, indicating that the cross-
contamination did not mask BDCA3+ mDC subset identity (Figure 4C). Finally, we 
derived DEPs between BDCA3+ mDCs and CD1c+ mDCs, using integration of 
protein and RNA data (Figures 4D and 4E). DEPs included IDO1, FUCA1, CD93, 
HLA-DOB, and TAP2 (high in BDCA3 mDCs) and also SIRPA, SIGLEC9, and 
CASP1 (high in CD1c+ mDCs). Several more DEGs by microarray showed a similar 
trend at the protein level but did not meet our stringent criteria (e.g., IRF8, CAMK2D, 
and TAP1; Table S8). Others were not found differentially expressed by proteomics 
or even showed an opposite trend. 
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Validation of DEPs 
To demonstrate the resource value of our integrated proteome and RNA analysis, 
we selected five cell-surface receptors for validation. We chose cell-surface 
receptors because these may reflect the ability of each subset to recognize 
dangerous agents, and could aid subset identification by flow cytometry. Using the 
latter technique, we confirmed differential expression of all five receptors: SIRPa and 
Siglec-9 were found on CD16+ monocytes and CD1c+ mDCs only; CD93 was 
especially high on BDCA3+ mDCs; Siglec-10 was unique to CD16+ monocytes; and, 
finally, CD163 was high on CD1c+ mDCs (Figure 5).  
Absence of Caspase-1 in pDCs Reflects Low Inflammasome Activity 
Previous transcriptome analysis already indicated that pDCs express lower levels of 
transcripts for proteins involved in antibacterial innate immune responses (Crozat et 
al., 2009). It was not clear whether this also translated to protein expression and 
functionality. Our proteome data now confirm that pDCs express lower levels of or 
lack TLR2, NAIP, HMOX, RAB27A, NCF2, and CASP1 (Figure 2; Table S7). 
Caspase-1, a crucial player in inflammasome function, was abundantly present in 
CD1c+mDCs and CD16+ cells but was lacking in pDCs (Figure 6A). In the BDCA3+ 
mDC-enriched sample, caspase-1 was present but at much lower levels than in 
CD1c+ mDCs. Importantly, protein quantification was based on 6, 11, or even 13 
peptides for BDCA3+ mDCS, CD1c+ mDCs, or CD16+ monocytes, respectively, 
while in pDCs, only a single peptide was mapped to caspase-1 that was not 
adequate for quantification, suggesting the absence or very low expression of this 
protein (Table S3). To further substantiate these MS data, we analyzed protein 
expression by western blot (WB). Caspase-1 was readily detected in CD1c+ mDCs 
and CD16+ monocytes but was present only at very low levels in pure BDCA3+ 
mDCs and not at all detected in pDCs (Figures 6B and S4). It should be noted that 
we did detect low levels of caspase-1 in pDCs isolated by magnetic beads but that 
protein expression was completely absent when cells were sorted to high purity 
(>99%) by flow cytometry (Figures 6 and S4). We next wondered whether pDCs 
would upregulate caspase-1 when activated. To test this, we incubated cells with the 
TLR7/8 ligand R848. Cell activation by TLR stimulation upregulated caspase-1 in 
CD1c+ mDCs but did not in pDCs (Figures 6C and S4). CD16+ monocytes also did 
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not further increase caspase-1 expression upon TLR stimulation. Upregulation of 
caspase-1 in BDCA3+ DCs could not be tested, because we did not manage to 
isolate a sufficient number of cells to test both resting and stimulated conditions by 
WB.  
Next, we were interested in the expression of other components of the 
inflammasome pathway. Only very few other proteins of this pathway were identified 
by MS: NAIP was also detected in all subsets except for pDCs, while the 
inflammasome- component NLRC4 was identified in CD16+ monocytes only (Figure 
2; Table S7). Exploration of the publicly available RNA expression data, however, 
indicated that low expression in pDCs was not restricted to caspase-1 but also 
included most other inflammasome components, as stated previously (Crozat et al., 
2009). CD16+ monocytes, in contrast, expressed high levels of inflammasome 
constituents, CD1c+ mDCs expressed more moderate levels, and BDCA3+ mDCs 
expressed low levels (Figure 6D). Together, these data strongly suggest an overall 
low presence of inflammasome-related proteins in pDCs. Consequently, pDCs may 
not be equipped to recognize inflammasome-activating stimuli or to synthesize and 
secrete IL-1b in response. All components of the pathway downstream of ATP 
recognition were low in pDCs compared to the other subsets (P2XR7, PANX, NLRP3, 
CARD8, PYCARD, and CASP1; Figure 6D), indicating that pDCs may not be 
equipped to respond to this danger-associated molecule. ATP can trigger the 
cleavage and secretion of IL-1b, provided that necrosis factor kB (NFkB) signaling is 
present at the same time to induce pro-IL-1b expression. As a proof of principle, we 
tested the ability of subsets to secrete IL-1b in response to ATP, preceded by 4-hr or 
overnight R848 stimulation to trigger NF-kB signaling via TLR7/8. Upregulation of 
activation marker CD83 and/or production of tumor necrosis factor a (TNF-a) was 
observed in all DC subsets, demonstrating functional NF-kB signaling (Figures 6E–
6G). IL-1b secretion was restricted to especially CD1c+mDCs and CD16+ mDCs. 
Thus, these data confirm that pDCs, indeed, lack IL-1b secretion in response to ATP. 
Of note, IL-18, which also requires caspase-1 for secretion, was readily secreted by 
ATP/R848-stimulated CD1c+ mDCs but not by pDCs (Figure S4). BDCA3+ mDCs 
were clearly activated by R848, as judged by the increased expression of CD83, yet 
hardly produced any cytokines (including IL-1b) under these circumstances (Figures 
6E–6G).  
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These experiments together demonstrate that the inflammasome/ caspase-1 
pathway is present and functional in CD1c+ mDCs and CD16+ monocytes but not in 
pDCs. Concordantly, pDCs do not secrete IL1b in response to ATP. 
DISCUSSION 
This study describes an elaborate proteome analysis of human blood-derived DC 
subsets and provides DC subset-specific protein signatures. This dataset holds 
unique information on the differences between DC subsets and reveals which 
differences, previously identified using mRNA, are really present at the protein level. 
Previously, Luber and colleagues analyzed the proteome of murine DC subsets 
(Luber et al., 2010), but large-scale proteomics of human DCs was thus far restricted 
to in-vitro generated monocyte-derived DCs (moDCs) and CD1c+ mDCs (Buschow 
et al., 2010; Schlatzer et al., 2012). The latter study reported 725 proteins expressed 
in resting and TLR-stimulated CD1c+ mDCs together, of which the majority (75%) 
was also identified, in the present analysis, in resting CD1c+ mDCs, along with a 
further 1,500 other proteins. The present dataset thus represents, to the best of our 
knowledge, the most complete quantitative proteome analysis of human DC subsets 
and provides a unique side-by-side comparison of these cells from the same donors.  
We report on nearly 400 differentially expressed proteins between the three main 
blood DC-like subsets. In addition, despite the presence of CD1c+ mDCs in the 
BDCA3+ mDC sample, we identify over 60 proteins differentially expressed between 
mDC subsets, of which we subsequently validated four by flow cytometry. The  
protein-based signatures we derived provide insight into possible functional 
differences between subsets. Although we cannot discuss in detail all the functional 
implications of the expression differences we have identified, several warrant further 
discussion. First, we demonstrate the abundant expression of the MCM family of 
proteins in CD1c+mDCs, but not in CD16+ monocytes or in pDCs. This protein 
family is essential for cell division. Thus, our data support previous findings that, in 
contrast to pDCs, a fraction of the blood mDC population may still be able to expand, 
possibly reflecting an incomplete differentiation state (Segura et al., 2012). Our data 
suggest that, like pDCs, CD16+ cells may completely lack the potential to expand. 
The remaining capacity of mDCs to divide is interesting from a clinical perspective, 
as it implies that mDCs after isolation may have the potential to be further expanded. 
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This concept may be of interest for the development of immunotherapies for cancer 
or chronic inflammatory diseases, where obtaining sufficient cell numbers is still a 
major hurdle.  
Second, HLA (human leukocyte antigen) molecule expression demonstrated some 
marked differences between subsets, suggesting subset-specific antigen 
presentation. CD1c+ mDCs not only highly express antigen-presenting CD1c but 
also highly expressed HLA-DQ, as compared to pDCs and CD16+ monocytes (but 
not HLA-DR). In agreement with a previous report, BDCA3+ cells uniquely 
expressed HLA-DO (Hornell et al., 2006). For these HLA types, either a clear (HLA-
DO) or a unique (HLA-DQ versus HLA-DR) biological function remains to be defined. 
Thus, the consequence of this subset-specific expression remains elusive. Third, 
many ER- and Golgi-located proteins were expressed at higher levels, specifically in 
pDCs. Previously, it has been shown that, in mice, pDCs and, to a lesser extent, 
CD8a+ DCs (the supposed murine equivalent of BDCA3+ DCs), were reported to 
display a constitutive activation of the unfolded protein response (UPR), as was 
indicated by the alternative splicing of XBP1 (Iwakoshi et al., 2007). The increase in 
UPR was required for ER expansion to facilitate rapid IFN-a biosynthesis and is 
reminiscent of plasma cell differentiation (Iwakoshi et al., 2007). The high levels of 
ER and glycoprotein biosynthesis and transport proteins that we describe in pDCs 
support the paradigm that immature pDCs are already prepared for rapid IFN-a 
synthesis. Proteins related to intracellular protein transport machinery are also 
overtly expressed in immature pDCs, and these may provide important clues to 
unravel the largely unknown IFN-a secretory route.  
From the identified DEPs, we confirmed five cell-surface receptors by flow cytometry: 
SIRPa and Siglec-9, which bind to CD47 and sialic acids, respectively, were found to 
be highly expressed on both CD16+ monocytes and CD1c+ mDCs. These receptors 
share a capacity to limit DC function and inflammation and are exploited by bacteria 
and malignant cells to evade immune responses (Laubli et al., 2014; Ohta et al., 
2010; Barclay and Van den Berg, 2014). Lack of these receptors may render cells 
insensitive to this evasion. CD1c+ mDCs uniquely expressed CD163, a scavenger 
receptor and PRR for bacteria (Kristiansen et al., 2001; Fabriek et al., 2009). Siglec-
10, which we found selectively expressed on CD16+ monocytes, is a putative 
adhesion receptor and PRR that has been reported to be expressed on CD16+ but 
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not CD16  monocytes, as well as on moDCs (Ancuta et al., 2009; Kivi et al., 2009; 
Li et al., 2001; Stephenson et al., 2014). Finally, BDCA3+ mDCs highly expressed 
CD93, which was reported to mediate phagocytosis and clearance of apoptotic cells 
and, as such, may act as an accessory to CLEC9A (Nepomuceno and Tenner, 1998; 
Norsworthy et al., 2004).  
Our proteome data provided strong evidence for a lack of caspase-1 in pDCs. We 
validated this by WB and show data to suggest that pDCs have a diminished 
presence of inflammasome pathway constituents. Concordantly, pDCs did not 
respond to inflammasome activator ATP, while CD1c+ mDCs and CD16+ monocytes 
did. Our data contradict those of several previous studies reporting on IL1-b 
secretion by pDCs (Hurst et al., 2009; Yu et al., 2010). These studies show pDCs to 
secrete pictograms of IL1b per milliliter of culture supernatant in response to TLR 
stimulation alone (without inflammasome activation). However, this level of IL1b is 
extremely low compared to production by CD16+ monocytes, which, we found, can 
secrete over a 100- fold more (nanograms of) IL1b per milliliter upon TLR and 
inflammasome stimulation. Furthermore, it is conceivable that traces (e.g., ±1%) of 
high IL1b-producing cells may be present in these pDC preparations isolated by 
magnetic beads, and such cells can contribute to the low amount of IL1b found to be 
secreted.  
Interestingly, our proteome data also indicated that, although expression of caspase-
1 was readily detected in the BDCA3+- enriched samples by proteomics, it was lower 
than in CD1+ mDCs and CD16+ DCs, a result we also verified using highly pure 
cells. Indeed, BDCA3+ mDCs responded less to inflammasome activation in the 
presence of TLR7/8 ligand. This stimulus matured BDCA3+ mDCs but did not induce 
cytokine secretion. However, low IL1-b production by BDCA3+ mDCs relative to 
CD1c+ mDCs, in response to the potent BDCA3+ mDC-activating stimulus poly(I:C), 
has also been reported (Jongbloed et al., 2010).  
Several recent publications have demonstrated that the pDC hallmarks type I IFN 
and IRF7 may directly inhibit IL-1b and inflammasome activity (Guarda et al., 2011; 
Salem et al., 2011). In pDCs, TLR7 activation by hepatitis C virus induced type I IFN 
secretion but induced neither IL-1b nor IL-18. In contrast, TLR7 activation in 
monocytes induced IL-1b and IL-18, rather than type I IFN (Chattergoon et al., 2014; 
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Dreux et al., 2012). The differentiation program involving IRF7 that allows pDCs to 
secrete large amounts of type I IFN may, thus, downregulate inflammasome pathway 
constituents, including caspase-1. Although this causal relation still awaits further 
experimental confirmation, this could switch the pDC response to TLR 
stimulation/NF-kB activation away from IL-1b and toward type I IFNs. A switch 
between type I IFNs and IL-1b could serve to prevent excessive damaging 
inflammation during antiviral responses.  
Taken together, the proteome dataset that we describe provides a rich resource to 
solidly establish the phenotypic and functional capacities of human DC subsets and 
to decipher the contribution of each subset to the initiation of immune responses. 
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EXPERIMENTAL PROCEDURES 
Cells 
DCs were isolated from apheresis products obtained from healthy volunteers after 
written informed consent was obtained and according to institutional guidelines and 
overseen by the local institutional review board (Commissie mensgebonden 
onderzoek [CMO]). Peripheral blood mononuclear cells (PBMCs) were purified via 
Ficoll density gradient centrifugation (Lucron Bioproducts), followed by magnetic-
bead (Miltenyi Biotec) or flow-cytometric isolation, and were directly lysed for MS or 
WB analysis or were used in in vitro experiments (see the following text and 
Supplemental Experimental Procedures for details). 
LC-MS/MS 
In brief: Tryptic peptides were analyzed using LC (Easy-nLC; Thermo Fisher 
Scientific) coupled to a 7-T linear ion trap Fourier-transform ion cyclotron resonance 
mass spectrometer model (LTQ FT Ultra, Thermo Fisher Scientific). See 
Supplemental Experimental Procedures for details. 
MS Data Processing 
Proteins were identified and quantified from raw mass spectrometric files using 
MaxQuant software, version 1.3.0.5 (Cox and Mann, 2008). A database search was 
performed in the Andromeda search engine (Cox et al., 2011) against the Human 
Uniprot database (86,749 entries, June 2012). The protein abundance was 
determined by MaxLFQ, as described by Cox et al. (2014). The MS proteomics data 
have been deposited to the ProteomeXchange Consortium via the PRIDE partner 
repository with the identifier PRIDE: PXD004678 (Vizcaıno et al., 2016). 
(http://proteomecentral.proteomexchange.org). See Supplemental Experimental 
Procedures for details. 
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Statistical Analysis of Protein and RNA Data 
See the Supplemental Experimental Procedures for details. Statistical analysis was 
performed in the R programming environment. Data were visualized using GENE-E 
software (http://www.broadinstitute.org/cancer/software/ GENE-E) and BioLayout 
Express3D (version 3.3) (Theocharidis et al., 2009). For PPI analysis, we used the 
STRING PPI web tool (version 10; http:// string-db.org/), and FA analysis was done 
using the DAVID web tool (https:// david.ncifcrf.gov/). 
Western Blotting and ELISA 
These were performed according to standard procedures. See Supplemental 
Experimental Procedures for details and antibodies used. 
In Vitro DC Activation 
Isolated DC-like subsets were resuspended in X-VIVO 15 (Cambrex) containing 2% 
pooled human serum (Sanquin). pDCs were supplemented with 10 ng/ml 
recombinant human IL-3 (rhIL-3; Cellgenix). Both cell types were stimulated for 4 hr 
or overnight with 4 mg/ml R848, followed by 45-min stimulation with 5 mM ATP 
(Sigma). Culture supernatant was taken for ELISA. 
ACCESSION NUMBERS 
The accession number for the MS proteomics data reported in this paper is PRIDE: 
PXD004678. 
SUPPLEMENTAL INFORMATION 
Supplemental Information includes Supplemental Experimental Procedures, four 
figures, and nine tables and can be found with this article online at 
http://dx.doi.org/10.1016/j.celrep.2016.08.023. 
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Legends 
Table 1. Subset identification markers uniquely identified.   
The numbers of peptide identified and quantified for each marker protein for each 
subsets. Shown markers were not identified in any of the other subsets for all donors. 
aPeptides were detected by releasing the FDR threshold of 0.01 and for which 
peptide spectra were manually validated.  
 
Figure 1.  Comparison of protein expression between 3 main blood DC-like subsets 
and integration with RNA data.  
(A) Volcano plots depicting protein expression differences (x-axis: 2log fold change) 
and the significance level (y-axis: -10log (t-test p-value)) comparing the indicated 3 
subsets.  Coloured dots represent proteins with a fold change of >2 and p<0.05 while 
gray dots represent proteins that did not match these criteria. Proteins specific to one 
of the 2 subsets compared were assigned a fold change of infinity. (See also Table 
S4) (B) Unsupervised hierarchical clustering of DC subsets using all proteins 
identified in at least 2 donors of at least one subset. (1-Pearson correlation) (C) 
Clustering of subsets based on 1218 DEPsby 3-group one-way ANOVA (p<0.05) or 
specifically expressed in one subtype in at least two donors. (D) Pearson correlation 
for each subtype between protein and RNA (microarray) expression levels  
(E)Hierarchical clustering of merged transcriptome and proteome data (DEPs only). 
(See also Table S5 and Figure S5.) 
Figure 2. Cell specific gene signatures derived from proteomics and transcriptomics.  
Protein based gene signatures for higher or lower expression in the three main 
subsets were derived from the merged proteome and transcriptome data based on 4 
levels of evidence: I) Specific protein expression/ absence for withRNA support II), 
differential protein expression with RNA support III), specific protein expression 
without RNA support and lastly IV) differential protein expression without RNA 
support. Proteins marked by asterisks were specifically identified by MS in two 
donors only  but were included because of  RNA support (e.g. “rescued”). The heat 
20
map colors represent the relative protein expressionin each DC subsetand donor. 
(See also Table S5.) 
Figure 3. Signature protein-protein interaction networks highlight functional 
differences between subsets.  
Signatures were used as input for STRING analysis (confidence level 0.4) to 
visualize possible connections between proteins. (See also Table S9.) Proteins 
indicated in blue  were included based on protein and RNA data and  red protein 
were pointed out by protein data only(see also methods and table S5). Important 
biological functions of sections of each network are indicated (based on functional 
enrichment see Table S9).     
Figure 4.  Pairwise comparison of BDCA3+ mDCs and CD1c+ mDCs.  
(A) Volcano plot depicting protein expression differences (x-axis: 2log fold change) 
and the significance level (y-axis: -10log (t-test p-value) as in figure 1. (B) Pearson 
correlation between protein and RNA (microarray)expression levels for all proteins. 
(C) Hierarchical clustering of merged z-scored transcriptome and proteome data of 
DEPs. (See also Table S6). (D) Heat map of the relative protein expression (LFQ) of 
proteins identified to be specifically (Level I and III) or differentially expressed (Level 
II or IV; by t-test), based on protein and RNA data evidence (Level I and II) or protein 
evidence only (Level III and IV).  
Figure 5. Confirmation of differentially expressed surface markers. 
 (A) Representative histogram of the expression of indicated surface markers by 
specific antibodies (lines) or isotype controls (grey area) on the 4 DC-like subsets. (B) 
Bar diagrams summarizing the specific fluorescence level measured by flow 
cytometry (FC) in 4 novel healthy donors  (isotype control antibody signal subtracted). 
Mean ± SEM of 4 healthy donors. All markers were found differentially expressed by 
one-way ANOVA (p<0.05), and with indicated significance by post-hoc Tukey's 
Multiple Comparison Test  *p<0.05, **p<0.01, *** <0.001. (C) Bar diagrams of mean 
LFQ values as obtained by MS analysis (3 donors).    
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Figure 6.  Absence of Caspase and inflammasome activity in pDCs.  
(A) Bar diagrams of LFQ values for Caspase-1 as obtained by MS analysis (3 
donors).  (B &C) Western blot analysis of DC subsets isolated by flow sorting  from 
two novel donors  lysed directly after isolation or (C) also afterovernight stimulation 
with R848. Shown is the signal for Caspase-1 and actin that were probed 
sequentially on the same blotting membrane. (D) Heat map of 2log intensity values 
of probes mapping to inflammasome components derived from  microarray data of 
the 4 subsets from 3 donors. (E) Flow cytometry based evaluation of the surface 
expression of the maturation marker CD83 on immature or ATP stimulated (4 hours 
45 min) subsets. Results of a representative donor are shown. (D & E) Secretion of 
indicated cytokines by pDCs and CD1c mDC after stimulation for 4 hours (D) or 
overnight (E) with R848 followed by 45 min with ATP by ELISA. Results are the 
mean values ± SEM obtained with cells from at least 4 donors. Significance of the  
effect of stimulation on each subset and cytokine was evaluated by a two-tailed 
Mann-Whitney test. *p<0.05, **p<0.01, *** <0.001, ns=non-significant. 
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 Peptides D1 Peptides D2 Peptides D3 
pDCs  
TLR9 5 10 11 
IL3RA (CD123) 2 3 7 
CLEC4C (BDCA2) 0 2 4 
TLR7
 
 0 4 7 
NRP1 (BDCA4) 1 0 1 
 
CD1c
+ 
   
CD1C 2 2 2 
 
BDCA3
+ 
   
IDO1 8 5 10 
TLR3 3 0 0 
THBD
a  
(BDCA3) 1 0 2 
CLEC9A
a
 0 1 0 
 
CD16
+ 
   
FCGR3A (CD16) 3 3 3 
 
Table 1. Subset identification markers uniquely identified. 
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Supplemental data 
 
 
Figure S1 related to figures 1 and 3: Assessment of DC purity by flow cytometry: Flow cytometry results 
for magnetic bead purified subset samples. Displayed for one donor are the side-scatter (SSC) and forward-
scatter (FSC; upper panel) and labelling for indicated subset  identification markers (middle panels) and B 
(CD19) and T (CD3) cell markers (lower panels). For each subset  the sorting gate used to quantify subset 
presence in the sample is marked by a red box. A summary of the percentage  of each subset(of total cells) 
present in the samples from all donors used for MS analysis is given in the table. For BDCA3+ DCs values are 
provided both for total CD11c+BDCA3+ cells (red box) and CD11c+BDCA3hi cells only (dotted red box).  
Please note that for the CD16+ monocyte sample, CD16 itself could not be used to reliably identify CD16+ cells 
after purification because of a decrease of CD16 label likely due to competition between the sorting antibody and 
the staining antibody. Therefore presence of CD16+ monocytes in this sample was based on CD11c only, which 
was justified by the concomitant absence of CD1c+ and BDCA3hi cells.   
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E. 
 
 
Figure S2 related to figures 1 and 3: Protein identification and coverage.  
(A-D) Venn Diagrams representing  the proteins identified in each donors for each subsets. (E)The percentage of 
complex components found back in each subset and donor for the indicated 6 essential protein complexes 
retrieved from the CORUM database. Coverage of these complexes provides a measure for the completeness of 
the measured proteome.  
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Figure S3 related to figure 6: Gating strategy for flow sorting of DC-subsets for Western blotting and 
functional analysis. A DC enriched fraction was obtained by magnetic bead depletion of non-DC PBMC 
constituents. This enriched fraction was subsequently sorted using a pool of lineage markers (CD3, CD14, 
CD16, CD19, CD20, and CD56; all excluded), HLA-DR (included) and the subset identification markers 
BDCA1, BDCA3, BDCA4 and CD16.  
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Figure S4 related to figure 6: Additional evidence for the absence of Caspase-1 and Caspase-1 dependent 
cytokine secretion in pDCs. (A) Additional Western blots for Caspase-1 and actin of magnetic bead isolated or 
flow cytometry sorted resting or R848 (ATP) stimulated DC-like subsets from one donor also used for MS 
analysis (donor 2) and 4 additional novel donors (4,5,7,8; Western blots of donors 6 and 9 are depicted in figure 
6 of the main manuscript). (B) Presence of IL-18 in the supernatant of CD1c+ mDCs or pDCs measured by 
ELISA after stimulation for 4 hours with R848 followed by 45 minutes of ATP. Shown is the mean amount 
secreted by 3 donors +/- SEM.    
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 Supplemental methods 
 
 
Cells 
For proteome analysis, DCs were isolated from aphaeresis products obtained from healthy volunteers after 
written informed consent and according to institutional guidelines. Peripheral Blood Mononuclear Cells 
(PBMCs) were purified from aphaeresis products via ficoll density gradient centrifugation (Lucron Bioproducts, 
Sint Martens-Latem, Belgium). To obtain peripheral blood leukocytes (PBLs), monocytes were depleted from 
PBMCs via adherence to plastic culture flasks. CD1c+ mDCs and CD16+ mDCs were isolated from PBMCs 
with a CD1c+ DC isolation kit and CD16+ monocyte isolation kit, respectively. BDCA3 myeloid DCs were 
isolated from PBLs by selection for BDCA3+ cells with a CD141 (BDCA3) isolation kit. Plasmacytoid DCs 
were purified from PBLs by positive selection using anti–BDCA-4–conjugated magnetic microbeads (all 
Miltenyi Biotec, Bergisch Gladback, Germany). DC purity was assessed by flow cytometry by staining for 
identification markers as indicated in Figure S1. Antibodies used  for CD11c, CD1c, CD16+, BDCA3,  BDCA2 
and CD123  were all from Miltenyi Biotec and as described previously (Schreibelt et al., 2012; Tel et al., 2013). 
Contamination with T cells and B cells was assessed by double staining of CD19 and CD3 (BD Biosciences). 
For Western blotting and ex vivo stimulation, DCs were isolated from PBMCs obtained from buffy coats of 
healthy donors  after written informed consent and according to institutional guidelines. For these experiments, 
pDCs and CD1c mDCs were either isolated by  flow sorting after an  initial DC-enrichment using a DC-
enrichment kit (Miltenyi Biotec) and subsequent DC-identificationusing Lin1-FITC (BD Biosciences; containing 
a pool of antibodies for CD3, CD14, CD16, CD19, CD20, and CD56; to be excluded) anti-HLA-DR-PE-Cy7 
(positive selection) and anti-BDCA3-APC, anti-BDCA4-PE (B, pDCs) (all from Miltenyi), anti-CD16-APC-Cy7 
(BD Biosciences) and anti-CD1c-PB (Biolegend). See figure S3A for the gating strategy. The four subsets were 
sorted using a FACS Aria II (BD Biosciences).For measuring the subset specific expression of 5 novel selected 
surface markers, PBMCs from healthy donors were stained for each of the surface marker using specific or 
isotype control antibodies  conjugated to PE (below) and either a cocktail containing CD45-APC-Vio770, CD14-
VioGreen, BDCA-3-APC, Clec9a-VioBrightFITC, CD20-PE-Vio770 (all from Miltenyi) CD1c-BV421 
(Biolegend) to identify CD1c mDC (CD45+, CD20-, CD14-, BDCA1+) and BDCA3+ mDC (CD45+, CD20-, 
CD14-, BDCA3+, CLEC9A+), or a cocktail containing CD45-V450 (BD Biosciences), BDCA-2-APC, CD123-
APC-Vio770 (both from Miltenyi), CD16-PE-Cy7, HLA-DR-BV510 and Lin2(CD56, CD3, CD14, CD20, 
CD19)-FITC (all from BD Biosciences) to identify pDCs (CD45+, Lin2-, HLA-DR+, BDCA2+, CD123+) and 
CD16+ monocytes (CD45+, Lin2-, HLA-DR+, CD16+).  Selected novel surface markers were stained using PE-
conjugated monoclonal antibodies against CD93 (Miltenyi Biotec), Siglec-9 (R&D systems), SIRPα 
(Biolegend), CD163 (BD Biosciences) and Siglec-10 (Biolegend).    
 
Protein Extraction/Sample Preparation for MS 
The purified and isolated DC subsets were resuspended in homogenisation buffer (20 mM Hepes (Roche) pH 
7.5, 250 mM sucrose (Baker) and complete protease inhibitor cocktail (Roche)) and disrupted by three cycles of 
freezing and thawing. The cells were centrifuged at 10,000 g to separate soluble and insoluble fractions and 
separated by SDS-PAGE using precasted 4-20% TRIS/Bis ready Gels (Biorad). Both soluble and insoluble 
fractions were loaded onto gels for MS analysis. For each subset in total 8ug of protein was loaded 
corresponding to 5-10.105 cells.  After electrophoreses the protein gel was stained with Novex Colloidal Blue 
(Invitrogen) and each lane was cut in to ten fractions. Gel fractions were subsequently treated with dithiothreitol 
(DTT) and iodoacetamide and digested by trypsin.  Digested samples were acidified to a final concentration of 
0.5% HAc and purified by STAGE tips as described before (Rappsilber et al., 2003). 
 
Liquid chromatography tandem mass spectrometry 
All the samples were analyzed using liquid chromatography (Easy n-LC; Thermo Fisher scientific) coupled to a 
7-T linear ion trap Fourier-Transform ion cyclotron resonance mass spectrometer model (LTQ FT Ultra, Thermo 
Fisher Scientific). Chromatography was performed with PicoTip columns (New Objective, Woburn, USA) of 15 
cm 100 µm in size and was packed with 3 µm Reprosil C18 beads (Dr. Maisch). Tryptic peptides were separated 
using a 90 min gradient from 12% buffer B to 40 % buffer B (buffer B contains 80% acetonitrile in 0.5% acetic 
acid) with a flow-rate of 300 nL/min. The LTQ-FT instrument was operated in data-dependent mode. Full-scan 
MS spectra of intact peptides (m/z 350-1500) with an automated gain control accumulation target values of 
1.000.0000 ions were acquired in the Fourier transform ion cyclotron resonance cell. The four most abundant 
ions were sequentially isolated and fragmented in the linear ion trap by applying collisional induced dissociation 
using an accumulation target value of 10.000, a capillary temperature of 100 ° C, and a normalized collision 
energy of 27%. A dynamic exclusion of ions previously sequenced was enabled. All unassigned charges states 
and singly charges ions were excluded from sequencing. A minimum of 200 counts was required for MS2 
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selection. Maximum injection times were set at 500 ms and 400 ms respectively for FT MS and IT MS/MS 
measurements. 
 
Mass spectrometry data processing and protein identification 
Proteins were identified and quantified from raw mass spectrometric files using MaxQuant software version 
1.3.0.5 (Cox and Mann, 2008). Peak lists were generated to contain the six most intense peaks per 100 Dalton 
mass window. Database search was performed in Andromeda search engine (Cox et al., 2011) against Human 
Uniprot database (86,749 entries, June 2012) supplemented with sequences of contaminant proteins. We 
included cysteine carbamidomethylation as a fixed modification and oxidized-methionine and protein N-terminal 
acetylation as variable modifications. The minimum peptide length was six amino acids and up to two tryptic 
mis-cleavages were considered for identification. The time window of 2 minutes was allowed to match peptides 
across different LC-MS/MS run from each fraction on basis of mass and retention time. At least two peptides, of 
which one was unique, were required for the protein identification. Protein quantification was based on both 
unique and “razor” peptides. The protein abundance was determined by MaxLFQ that is based on comparison of 
individual peptide intensities over all samples as described by (Cox et al., 2014) and LFQ intensities values were 
normalized across biological replicates using median value. For ANOVA and hierchical clustering (below) 
missing values were filled by random values from the lower end of the expression value spectrum using Perseus 
software (version 1.4.2.23; Tyanova et al., 2016). Raw MS data are available at proteome central (accession 
number PXD004678) (http://proteomecentral.proteomexchange.org) 
 
Statistical analysis of protein data 
Since DC subsets derived from the third donor were of lower purity further use of these samples is only justified 
when sufficiently stringent criteria are used. Therefore, to extract reliable and informative data, observed protein 
expression differences were only used when present in at least two out of three donors or when confirmed by 
additional data from independent studies. 
The list of differentially expressed proteins for hierarchical clustering and signature generation was obtained by 
merging subsets specifically expressed proteins (present in at least 2 out of 3 donors and absent in all other 
subsets in all donors) to proteins that were called significantly differentially expressed by 3-group one-way 
ANOVA (p-0.05) on the imputation supplemented protein data. On the ANOVA p-values a bonferoni-Holms 
correction for multiple testing was performed (Table S7). Furthermore, to prevent false positive results, proteins 
expressed below a measured LFQ value of 217 were excluded from ANOVA because for these proteins the 
imputed LFQs to fill missing values may exceed that of the measured values. ANOVA was performed in the R 
programming environment.   
 
Data processing of publically available transcriptome data 
The raw microarray data (CEL files) were downloaded from ArrayExpress (accession: E-TABM-34) for human 
DC subsets (pDCs, BDCA3+ DCs, CD1c+ DCs, CD16+ cells). The raw data was normalized using the RMA 
normalization function of the affy package and mapped using hgu133plus2.db annotation package (Gautier et al., 
2004). After data normalization, only the genes that had an expression level above background in at least 1 out of 
4 populations with a differential expression between at least 2 cell types were considered. In cases where 
multiple probes were related to a gene, only the probe expressed highest across all samples was considered. 
 
RNA sequencing  
For RNA sequencing RNA was extracted from subsets lysed immediately after harvesting in Trizol reagent 
(Thermo fisher) and forcing the lysate trough a 25 gauge syringe for 10 times.  RNA was subsequently isolated 
using and RNeasy kit and on-column DNase treatment ( both from Qiagen). Thereafter for each sample 250 ng 
of total RNA was treated by Ribo-Zero rRNA Removal Kit (epicentre) to remove ribosomal RNAs (according to 
manufacturer instructions) and mRNA was purified using the (Zymo research). Subsequently purified RNA was 
fragmented using (5x) fragmentation buffer (200 mM Tris acetate pH 8.2, 500 mM potassium acetate and 150 
mM magnesium acetate) and incubated at 95°C for 90 seconds. After a new round of purification, first strand 
cDNA was synthesized from fragmented RNA with SuperscriptIII (Invitrogen). First strand cDNA was purified 
by MinElute cleanup kit (Qiagen) and second strand cDNA was prepared in the presence of dUTP instead of 
dTTP and using random hexamers. Double stranded cDNA was purified by Qiagen mini elute columns and used 
for Illumina sample prepping and sequenced according to the manufacturer’s instructions. The RNAseq reads 
were mapped to HG18 and used to calculate RPKM values (reads per kilobase of gene length per million reads) 
(Mortazavi et al., 2008). 
Hierarchical clustering 
The hierarchical clustering of samples and genes was performed based on 1-Pearson correlation in combination 
with average linkage clustering using GENE-E software (http://www.broadinstitute.org/cancer/software/GENE-
E).Proteome and transcriptome data were mapped based on similarity of the gene symbol. Both datasets were 
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separately normalized and z-scored in the R programming environment (mean to 0 and variance to 1). From the 
merged dataset differentially expressed proteins we extracted (present in at least 2 out of 3 donors and absent in 
all other subsets in all donors plus proteins called significantly differentially expressed by 3-group one-way 
ANOVA (p-0.05).  The thus obtained dataset was used for hierarchical clustering of samples.  
 
Signature generation 
For proteins highly or lowly expressed in each of the 3 subsets (pDCs, CD1c+ mDC, CD16+ monocytes), 
protein signatures were generated by combining protein and transcriptome data in 4 levels of evidence according 
to the criteria below (Table S7).  
For the high expression signatures for each subset the criteria were:  
Level I) specific proteins with RNA support. Protein: Is specifically expressed in the subset in 3 out of 3 donors 
but absent in all other subsets. RNA: MinMax >1.5 fold for linear values (for Log2 values, FC = Log2(Min)cluster-
subset(s)-Log2(Max)other subsets> 0.58). Proteins specifically expressed only in 2 out of 3 donors were “rescued” and 
included in the signatures because of RNA support (MinMax >1.5 fold).  
Level II) differentially expressed proteins with RNA support. Protein: 3-group one-way ANOVA proteomics 
with multiple testing correction (BH) <0.05 and expression in the subset(s) in at least 2 out of 3 donors. Post-hoc 
t-test comparisons proteomics for the high expressing subset(s) against other subset p<0.05 and a fold change of 
>2. RNA: MinMax >1.5 fold for linear values. ANOVA significant proteins (p<0.05) lost by multiple testing 
correction but meeting all other criteria and supported by RNA expression (MinMax >1.5 fold) were included in  
Table S7 as low confidence DEPs. 
Level III) Specific protein expression without RNA support. Protein: As level I. RNA: Criteria Level I are not 
met or no data available. Proteins specifically expressed in only 2 out of 3 donors were also included Table S7 as 
low confidence DEPs 
Level IV) Differential protein expression without RNA support. Protein as in level II; RNA: Conditions level II 
are not met or no data available. 
 
For the proteins lowly expressed in subset the criteria were as above with the following modifications:  
Level I) Protein: Absent in the cluster-subset but present in all other subsets; RNA: Minimum expression in other 
subsets over maximum in the subset > 1.5 fold. Proteins absent in the cluster-subset in 3/3 donors but present in 
only 2/ 3 donors in (any of) the other subsets are  
included in Table S7 as low confidence DEPs. 
Level II) Protein: Presence in the other subset in at least 2 out of 3 donors.  
Level III) Protein as for level I. Proteins absent in the cluster-subset in 3/3 donors but present in only 2/ 3 donors 
in (any of) the other subsets were also included in Table S7 as low confidence DEPs. 
Level IV) Protein as for level II. RNA: Did not meet criteria level II or no data available.  
 
Finally, proteins identified in at least two donors in one subset but not identified as differentially expressed 
according to the signature criteria above, yet found differntially expressed based on RNA expression data are 
given in supplementary table S8.    
 
Extracting DEPs between BDCA3+ mDCs and CD1c+ mDCs:  
To extract DEPs we aplied roughly the same structure as for signature generation but now based on t-tests and 
with the follwing specific rules: 
Level I: present in > 2/3 donors in one of the 2 subsets, no presence in the other subset (3/3), also significant at 
RNA level by Min Max (> 1.5 fold) 
Level II: t-test significant (p-value <0.05, FC >2), also significant at RNA by Min max (> 1.5 fold) 
Level III: present in > 3/3 donors in one of the 2 subsets, no presence in the other subset (3/3), no RNA data or 
significance. Proteins only specifically present in 2/3 donors are only present in Table S7 as low confidence 
DEPs 
Level IV: t-test significant (p-value < 0.01, FC>2); no presence in the other subset (3/3), no RNA data or 
significance. Proteins with a t-test p-value between 0.01 and 0.05 are only present in Table S7 as low confidence 
DEPs 
 
Protein-protein Interaction, GO and pathway analysis  
Signatures depicted in figure 2 were used as input for protein-protein interaction (PPI) analysis using the 
STRING PPI web tool (http://string-db.org/; version 10). A confidence score of 0.4 was used as a cut-off for 
protein-protein interaction allowing all sources of evidence. Obtained confidence scores for each interaction can 
be found in table S9. The generated interaction networks were uploaded in Biolayout express 3D (version 3.3) 
for graphical representation  (Theocharidis et al., 2009). Signatures were mapped onto functional categories 
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using the functional annotation clustering algorithm in the DAVID web tool (https://david.ncifcrf.gov/) using 
standard settings. Full functional annotation output can be found in Table S9.  
 
Western blotting  
Reduced cells lysates were loaded on a 10% SDS-gel and transferred to a PVDF membrane. Caspase-1 was 
stained with the caspase-1-p10 (C-20): sc-515 antibody (Santa Cruz Biotechnology) and Actin with anti-Actin 
(20-33) antibody (Sigma). Blots were analyzed on the Odyssey imaging system. 
 
ELISA 
Cytokine production of IL-1β (R&D Systems) and TNF (eBioscience) was measured by ELISA. IL-18 
production was analyzed by using Luminex. To monitor activation, cells were stained for 30 minutes with anti-
CD83-FITC (BD Biosciences)  and analyzed by flow cytometry. 
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Overview of supplemental Tables: 
 
Table S1: Correlation between biological and technical replicates_related to figures 1 and 4 
Tab1: Technical replicates 
Tab2: biological replicates 
Table S2: Identified proteins_related to figures 1 and 4: Protein table of all proteins identified in all 4 subsets 
and all 4 donors (at least 2 in one subsets, no LFQ restrictions) 
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Table S3: Identified peptides_related to figures 1 and 4: Peptide table of all peptides identified in all 4 subsets in 
all 4 donors 
Table S4: Pairwise comparison of subsets_related to figures 1 and 4: t-test of all combinations of all 4 subsets 
Table S5: RNA sequencing data donor 2_related to figures 1 and 4 
Table S6: Merged RNA and protein data_related to figures 1 and 4 
Tab1: merged table RNA and protein data  (MA and RNA seq)  
Tab2: correlation of RNA (MA and RNA seq)  
Table S7: Signatures_related to figures 2 and 4: Signatures for all 6 groups in the 3 subset comparison and for 
BDCA3 compared to CD1c+ mDC  
Tab1: pDC vs CD1c & CD16 up 
Tab2: pDC vs CD1c & CD16 down  
Tab3: CD1c vs pDC& CD16 up 
Tab4: CD1c vs pDC% CD16 down 
Tab5: CD16vs pDC&CD1c up 
Tab6: CD16 vs pDC&CD1c down 
Tab7: BDCA3 vs CD1c up 
Tab8: CD1c vs BDCA3 up 
Table S8: Table S8_DEGs not confirmed by proteomics_related to figure 2 and 4  
Tab1: pDC vs CD1c & CD16 up 
Tab2: pDC vs CD1c & CD16 down  
Tab3: CD1c vs pDC& CD16 up 
Tab4: CD1c vs pDC% CD16 down 
Tab5: CD16vs pDC&CD1c up 
Tab6: CD16 vs pDC&CD1c down 
Tab7: BDCA3 vs CD1c up 
Tab8: CD1c vs BDCA3 up 
Table S9: PPI and FA analysis_ related to figure 3 
Tab1: pDC vs CD1c & CD16 up 
Tab2: pDC vs CD1c & CD16 down  
Tab3: CD1c vs pDC& CD16 up 
Tab4: CD1c vs pDC% CD16 down 
Tab5: CD16vs pDC&CD1c up 
Tab6: CD16 vs pDC&CD1c down 
Tab7: BDCA3 vs CD1c up 
Tab8: CD1c vs BDCA3 up 
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